Kyle Holen: Some time with us. We’re really excited about sharing with you some new data that we just shared earlier today on one of our assets, 4359, which is quickly becoming one of our newest late-stage assets similar to INT, which you’ve heard a lot about.
I’m going to walk you through some of the INT data. Then, we’re pleased to have some experts in the field who have joined us tonight to talk to you about melanoma and the data that was presented on 4359. That’s Dr. Sullivan and Dr. Pinato. We’ll bring them up shortly.
But before we do, let me just talk to you about our pipeline.
At Moderna, we use mRNA in many different creative ways. We have personalized therapies, which is our Intismeran autogene program, and I’ll share a little bit about that.
We also have some off-the-shelf therapies. Those are our cancer antigen therapies, which we affectionately call our CATs (C-A-T).
Additionally, we have a T-cell engager program, and I’ll share some preliminary information about where we are with our T-cell engagers.
Lastly, we have some cell therapy enhancing and in vivo cell therapy programs, which are also really exciting for us as we advance them into the clinic.
All of these programs, we believe, hold the promise of potential efficacy across a broad range of indications as well as different therapeutic areas.
https://seekingalpha.com/article/4830875-moderna-inc-mrna-shareholder-analyst-call-transcript?source=feed_all_articles